Khalil Ghasemi Falavarjani1, Nicholas A Iafe2, Jean-Pierre Hubschman2, Irena Tsui2, Srinivas R Sadda3, David Sarraf4. 1. Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 2Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, United States 3Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. 2. Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 4Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States. 3. Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 2Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, United States. 4. Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States 4Stein Eye Institute, University of California Los Angeles, Los Angeles, California, United States 5Greater Los Angeles VA Healthcare Center, Los Angeles, California, United States.
Abstract
Purpose: To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion. Methods: In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection. Results: The mean interval between baseline and follow up OCTA was 32.5 ± 9.4 (range, 21-50) days. Foveal and parafoveal vessel density in the SCP and DCP were not significantly different before and after intravitreal injection (all P > 0.1), nor was FAZ area (P = 0.48 and P = 0.42, respectively). No significant difference was found between eyes with diabetic macular edema and those with retinal vein occlusion with respect to the mean change of vessel density and FAZ area (all P > 0.05). Conclusions: In this pilot study, retinal capillary density and FAZ area remained statistically unchanged in the short-term after a single intravitreal injection of an anti-VEGF agent.
Purpose: To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion. Methods: In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection. Results: The mean interval between baseline and follow up OCTA was 32.5 ± 9.4 (range, 21-50) days. Foveal and parafoveal vessel density in the SCP and DCP were not significantly different before and after intravitreal injection (all P > 0.1), nor was FAZ area (P = 0.48 and P = 0.42, respectively). No significant difference was found between eyes with diabetic macular edema and those with retinal vein occlusion with respect to the mean change of vessel density and FAZ area (all P > 0.05). Conclusions: In this pilot study, retinal capillary density and FAZ area remained statistically unchanged in the short-term after a single intravitreal injection of an anti-VEGF agent.
Authors: Giselle Lynch; Jorge S Andrade Romo; Rachel Linderman; Brian D Krawitz; Shelley Mo; Amir Zakik; Joseph Carroll; Richard B Rosen; Toco Y P Chui Journal: Biomed Opt Express Date: 2018-11-05 Impact factor: 3.732
Authors: Osama A Sorour; Almyr S Sabrosa; A Yasin Alibhai; Malvika Arya; Akihiro Ishibazawa; Andre J Witkin; Caroline R Baumal; Jay S Duker; Nadia K Waheed Journal: Int Ophthalmol Date: 2019-05-22 Impact factor: 2.031
Authors: Akihiro Ishibazawa; Lucas R De Pretto; A Yasin Alibhai; Eric M Moult; Malvika Arya; Osama Sorour; Nihaal Mehta; Caroline R Baumal; Andre J Witkin; Akitoshi Yoshida; Jay S Duker; James G Fujimoto; Nadia K Waheed Journal: Invest Ophthalmol Vis Sci Date: 2019-10-01 Impact factor: 4.799
Authors: Jesse J Jung; Daryle Jason G Yu; Anne Zeng; Michael H Chen; Yue Shi; Marco Nassisi; Kenneth M Marion; Srinivas R Sadda; Quan V Hoang Journal: Ophthalmol Retina Date: 2020-05-07
Authors: Ahmed Roshdy Alagorie; Muneeswar Gupta Nittala; Swetha Velaga; Brenda Zhou; Alexander M Rusakevich; Charles C Wykoff; SriniVas R Sadda Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Thomas S Hwang; Ahmed M Hagag; Jie Wang; Miao Zhang; Andrew Smith; David J Wilson; David Huang; Yali Jia Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389